CIK 0000744218 · Large accelerated filer
Celldex Therapeutics, Inc.
Sign in to watch- Ticker
- CLDX
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 133191702
- Phone
- 908-200-7500
- Business address
- 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827
- Former names
- AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-25 | Lawver Teri L SVP & Chief Commercial Officer | Grant or award · Incentive Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2026-06-25 | Jimenez Freddy A. SVP & GENERAL COUNSEL | Grant or award · Incentive Stock Option (right to buy) | +93,000 | 93,000 | ||
| 2026-06-25 | Torres Denice Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-06-25 | Heath-Chiozzi Margo SVP OF REGULATORY AFFAIRS | Grant or award · Incentive Stock Option (right to buy) | +95,000 | 95,000 | ||
| 2026-06-25 | Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Grant or award · Incentive Stock Option (right to buy) | +95,000 | 95,000 | ||
| 2026-06-25 | Martin Samuel Bates SVP AND CFO | Grant or award · Incentive Stock Option (right to buy) | +93,000 | 93,000 | ||
| 2026-06-25 | Jain Rita Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-06-25 | Crowley Elizabeth SR. VP & CPDO | Grant or award · Incentive Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2026-06-25 | Young Diane C. SVP, CHIEF MEDICAL OFFICER | Grant or award · Incentive Stock Option (right to buy) | +57,000 | 57,000 | ||
| 2026-06-25 | NEIL GARRY ARTHUR Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-06-25 | Cohen Cheryl Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-06-25 | Brownlie Keith L Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-06-25 | Marucci Anthony S PRESIDENT & CEO | Grant or award · Incentive Stock Option (right to buy) | +375,000 | 375,000 | ||
| 2026-06-25 | KELER TIBOR EXECUTIVE VP & CSO | Grant or award · Incentive Stock Option (right to buy) | +115,000 | 115,000 | ||
| 2026-06-25 | CONRAD HERBERT J Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-06-25 | PEPIN RONALD SR. VP & CBO | Grant or award · Incentive Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-06-25 | MARINO JAMES J Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-06-25 | PENNER HARRY JR Director | Grant or award · Non-Qualified Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2026-01-02 | Martin Samuel Bates SVP AND CFO | Option exercise | +4,817 | $10.38 | $50K | 32,942 |
| 2026-01-02 | Martin Samuel Bates SVP AND CFO | Option exercise · Incentive Stock Option (Right to Buy) | −4,817 | 58,815 |
Page 1 of 10 · 182 trades